Form 4: Cero Therapeutics Holdings Director, Lindsey Rolfe, Acquires Stock Options
SEC Form 4 Filing
Lindsey Rolfe, a director at Cero Therapeutics Holdings, acquired stock options for 112,500 shares on March 25, 2024.
Summary
- On March 25, 2024, Lindsey Rolfe, a director of Cero Therapeutics Holdings, Inc. (CERO), acquired stock options for 112,500 shares.
- The options have an exercise price of $1.77.
- The shares underlying the options vest in 36 monthly installments, contingent upon continued service.
- Following the transaction, Rolfe directly owns 112,500 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock option grants. The director's acquisition of options could be seen as a slightly positive signal, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Lindsey Rolfe acquired stock options. |
| 03/24/2034 | Expiration date of the stock options. |
| 03/27/2024 | Date of signature on the Form 4 filing. |
Keywords
Cero Therapeutics Holdings, Director, Stock Options, Beneficial Ownership, Form 4, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.